Black Diamond Therapeutics (BDTX) Enterprise Value (2018 - 2021)
Historic Enterprise Value for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to -$235.0 million.
- Black Diamond Therapeutics' Enterprise Value rose 2944.23% to -$235.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was -$235.0 million, marking a year-over-year increase of 2944.23%. This contributed to the annual value of -$315.1 million for FY2020, which is 10370.8% down from last year.
- According to the latest figures from Q3 2021, Black Diamond Therapeutics' Enterprise Value is -$235.0 million, which was up 2944.23% from -$263.5 million recorded in Q2 2021.
- Black Diamond Therapeutics' 5-year Enterprise Value high stood at -$39.6 million for Q2 2019, and its period low was -$357.2 million during Q1 2020.
- Over the past 4 years, Black Diamond Therapeutics' median Enterprise Value value was -$219.7 million (recorded in 2020), while the average stood at -$197.3 million.
- As far as peak fluctuations go, Black Diamond Therapeutics' Enterprise Value crashed by 69878.12% in 2020, and later surged by 2944.23% in 2021.
- Quarter analysis of 4 years shows Black Diamond Therapeutics' Enterprise Value stood at -$51.7 million in 2018, then tumbled by 199.39% to -$154.7 million in 2019, then crashed by 103.71% to -$315.1 million in 2020, then increased by 25.41% to -$235.0 million in 2021.
- Its Enterprise Value was -$235.0 million in Q3 2021, compared to -$263.5 million in Q2 2021 and -$290.1 million in Q1 2021.